Market Cap
$679.2M
MDXG
MIMEDX GROUP, INC.
$4.59 ▼ -1.08%
Prev close $4.64Market cap$679.2M
ConsensusStrong Buy
12-mo target$7.40 (+61.2%)
▲ Bullish
Analyst conviction 9/10
High Impact Filing (7/10)29 New Institutional Positions21 Institutional Exits Healthcare & Medical Devices
Snapshot
The big-picture read on MDXG right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Strong Buy (91%)
Inst. Holders
50 funds
Inst. Value
$206.5M
Inst. Activity
29 buys / 21 sells
Social Sentiment
67° Warm
SEC Reports
4
Price chart 30d +3.6%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 23, 2026 other
MIMEDX Announces Favorable Federal Court Ruling in AXIOFILL® Regulatory Classification Matter
Court Vacates FDA Determinations That AXIOFILL Is Not Minimally Manipulated and Should Be Classified
Jul 2, 2026 Insider
DOUG RICE surrendered for taxes 12,749 shares
Chief Financial Officer @ $3.95 ($50.4K)
Jun 30, 2026 Inst.
GOLDMAN SACHS GROUP INC — DOUBLED
2,665,562 shares ($10.3M)
Jun 30, 2026 Inst.
DIMENSIONAL FUND ADVISORS LP — TRIM
1,944,852 shares ($7.5M)
Jun 24, 2026 Insider
Maersk-Moller Kimberly surrendered for taxes 19,820 shares
Chief Commercial Officer @ $3.83 ($75.9K)
Jun 10, 2026 Insider
Jun 2, 2026 SEC PUHY DOROTHY E was granted 50,913 shares
Director @ $3.64 ($185.3K)
The Federal Circuit dismissed the appeal in Mimedx Group, Inc. v. Surgenex, LLC by agreement of the parties, with each s
COURT-RULING — Impact 5/10
Jun 2, 2026 Event
Mimedx Group, Inc. v. Surgenex, LLC
Court ruling from Court of Appeals for the Federal Circuit. Docket: 26-1794
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
91% rate it Buy or better · 11 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Aug 27, 2026 | Craig-Hallum | MAINTAIN | Buy | 54% |
| Aug 17, 2026 | Cantor Fitzgerald | REITERATE | Overweight | 49% |
| Apr 30, 2026 | Citizens | MAINTAIN | Market Outperform | 38% |
| Apr 20, 2026 | Citizens | MAINTAIN | Market Outperform | 38% |
| Apr 17, 2026 | Craig-Hallum | MAINTAIN | Buy | 54% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 2 | 8 | 1 | 0 | 0 | 91% | |
| Aug 1, 2026 | 2 | 8 | 1 | 0 | 0 | 91% | |
| Jul 1, 2026 | 2 | 8 | 1 | 0 | 0 | 91% | |
| Jun 1, 2026 | 2 | 9 | 1 | 0 | 0 | 92% | |
| May 1, 2026 | 2 | 9 | 1 | 0 | 0 | 92% | |
| Apr 1, 2026 | 2 | 9 | 1 | 0 | 0 | 92% | |
| Mar 1, 2026 | 2 | 9 | 1 | 0 | 0 | 92% | |
| Feb 1, 2026 | 2 | 8 | 1 | 0 | 0 | 91% |
Price targets
Where 5 covering analysts think MDXG trades over the next 12 months.
$7.40 +61.2% upside Strong Buy
Current$4.59 Low$6.00 Median$8.00 High$8.00 5 analysts
$6.00$8.00
Analyst rating None as of Oct 2, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
67°
Warm
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
4 SEC filing reports analyzed · 1 bullish, 1 bearish, 0 mixed, 2 neutral · avg impact 4.5/10.
BULLISHCOURT-RULING5/10
The Federal Circuit dismissed the appeal in Mimedx Group, Inc. v. Surgenex, LLC by agreement of the
Jun 2, 2026
NEUTRALDEFA14A3/10
MiMedx Group filed a DEFA14A (additional definitive proxy soliciting materials). The substantive con
Apr 29, 2026
NEUTRALPRESS-RELEASE3/10
MiMedx Group announced it will report Q1 2026 earnings on April 29, 2026, after market close, follow
Apr 22, 2026
BEARISH8-K7/10
MiMedx Group announced a cost reduction initiative including the elimination of the Chief Operating
Apr 16, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 23, 2026
other
MIMEDX Announces Favorable Federal Court Ruling in AXIOFILL® Regulatory Classification Matter
Court Vacates FDA Determinations That AXIOFILL Is Not Minimally Manipulated and Should Be Classified as a Biological Product
Sep 15, 2026
short_interest_report
Short Interest: MDXG up 15% to 10.8M shares
Settlement 2026-09-15 | Days to cover: 10.87 | ≈7.38% of shares outstanding (est.)
Sep 10, 2026
short_volume
Short Volume: MDXG — 69.1% short (0.4M / 0.6M)
Short: 402,868 | Exempt: 2 | TRF Vol: 583,036 | Short Ratio: 69.1% | Off-exchange volume (dark pool + OTC)
Sep 8, 2026
other
MIMEDX to Participate in Upcoming Investor Conferences
MARIETTA, Ga., Sept. 08, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its se
Aug 20, 2026
short_volume
Short Volume: MDXG — 77.3% short (0.4M / 0.5M)
Short: 391,987 | Exempt: 45 | TRF Vol: 507,121 | Short Ratio: 77.3% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.01 | $-0.02–$0.05 | -95.5% | +0.0% | 0↑ 2↓ | $0.1B | 3 |
| Next Q | $0.04 | $0.00–$0.07 | -71.4% | +0.0% | 0↑ 2↓ | $0.1B | 3 |
| Current FY | $-0.06 | $-0.10–$0.03 | -112.6% | -6.3% | 0↑ 1↓ | $0.3B | 3 |
| Next FY | $0.20 | $0.04–$0.39 | 452.9% | +15.4% | 1↑ 1↓ | $0.3B | 3 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $0.007 | — |
| 7d ago | $0.007 | — |
| 30d ago | $0.007 | — |
| 60d ago | $-0.003 | +0.010 |
| 90d ago | $-0.003 | +0.009 |
Institutional ownership
Which big funds own MDXG (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $206.5M total value (53,642,972 shares) as of 2026-Q2. Top holders: BlackRock,, STATE, VANGUARD. Net buying activity: 29 institutions added/increased vs 21 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 12,154,466 | $46.8M | 22.7% | — |
| STATE STREET CORP | 5,578,920 | $21.5M | 10.4% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 5,187,053 | $20.0M | 9.7% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 3,143,488 | $12.1M | 5.9% | — |
| GOLDMAN SACHS GROUP INC | 2,665,562 | $10.3M | 5.0% | DOUBLED +124.8% |
| AQR CAPITAL MANAGEMENT LLC | 2,467,005 | $9.5M | 4.6% | — |
| RENAISSANCE TECHNOLOGIES LLC | 2,444,230 | $9.4M | 4.6% | — |
| DIMENSIONAL FUND ADVISORS LP | 1,944,852 | $7.5M | 3.6% | TRIM -27.8% |
| NORTHERN TRUST CORP | 1,317,575 | $5.1M | 2.5% | ADD +28.8% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1,290,476 | $5.0M | 2.4% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| GOLDMAN SACHS GROUP INC | DOUBLED | 1,185,561 | 2,665,562 | +124.8% | $10.3M |
| DIMENSIONAL FUND ADVISORS LP | TRIM | 2,694,002 | 1,944,852 | -27.8% | $7.5M |
| NORTHERN TRUST CORP | ADD | 1,023,106 | 1,317,575 | +28.8% | $5.1M |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | ADD | 775,841 | 1,266,571 | +63.3% | $4.9M |
| MORGAN STANLEY | ADD | 812,742 | 1,043,286 | +28.4% | $4.0M |
| Qube Research & Technologies Ltd | TRIM | 1,651,519 | 990,228 | -40.0% | $3.8M |
| JANE STREET GROUP, LLC | ADD | 525,472 | 792,311 | +50.8% | $3.1M |
| Squarepoint Ops LLC | ADD | 329,216 | 571,930 | +73.7% | $2.2M |
| AMERICAN CENTURY COMPANIES INC | ADD | 382,824 | 538,392 | +40.6% | $2.1M |
| Creative Planning | DOUBLED | 135,348 | 520,962 | +284.9% | $2.0M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
10 insiders, 25 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 2, 2026 | DOUG RICE | Chief Financial Officer | TAX W/H | 12,749 | $3.95 | $50.4K |
| Jun 24, 2026 | Maersk-Moller Kimberly | Chief Commercial Officer | TAX W/H | 19,820 | $3.83 | $75.9K |
| Jun 10, 2026 | PUHY DOROTHY E | Director | AWARD | 50,913 | $3.64 | $185.3K |
| Jun 10, 2026 | BIERMAN JAMES L | Director | AWARD | 50,913 | $3.64 | $185.3K |
| Jun 10, 2026 | Olson Tiffany | Director | AWARD | 50,913 | $3.64 | $185.3K |
| Jun 10, 2026 | HAWKINS WILLIAM A | Director | AWARD | 50,913 | $3.64 | $185.3K |
| Jun 10, 2026 | Newton Todd | Director | AWARD | 50,913 | $3.64 | $185.3K |
| Mar 13, 2026 | Hulse William Frank IV | General Counsel and CAO | TAX W/H | 20,245 | $4.38 | $88.7K |
| Mar 13, 2026 | Maersk-Moller Kimberly | Chief Commercial Officer | TAX W/H | 6,762 | $4.38 | $29.6K |
| Mar 10, 2026 | Hulse William Frank IV | General Counsel and CAO | TAX W/H | 61,460 | $4.50 | $276.6K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for MDXG.
Shares short
10,760,703
Settlement Sep 15, 2026
Change vs prior
+14.7%
Semi-monthly cycle
Days to cover
10.9
At avg daily volume
Of shares outstanding
≈7.4%
Estimate — not % of float
All MDXG filing & press-release reports (4)
- COURT-RULING reportJun 2, 2026
- DEFA14A reportApr 29, 2026
- PRESS-RELEASE reportApr 22, 2026
- 8-K reportApr 16, 2026